We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Médicins sans Frontières is to address the lack of available treatments for many diseases that afflict the world’s poor by launching an ambitious international effort to create a virtual industry driven by public needs rather than share price.

The Drugs for Neglected Diseases Initiative (DNDI) — which was formally launched in New York last month — will research, develop and produce drugs for diseases that have been ‘neglected’ because they affect mainly people in the developing world, and so have poor commercial prospects.

The Paris-based charity has put up an initial US$1 million for five pilot projects to develop and produce drugs for the parasitic diseases visceral leishmaniasis and sleeping sickness. More funding will later be sought from foundations and governments.

Link to full text

Reference: Nature 416, 465 (2002)

Related topics